These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 24681838)
21. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916 [TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol and rheumatoid arthritis. Just another TNF alpha antagonist, no therapeutic advantage. Prescrire Int; 2010 Dec; 19(111):279. PubMed ID: 21355379 [TBL] [Abstract][Full Text] [Related]
24. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976 [No Abstract] [Full Text] [Related]
25. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X Ann Rheum Dis; 2015 Jan; 74(1):96-103. PubMed ID: 24092417 [TBL] [Abstract][Full Text] [Related]
26. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. Harigai M; Takamura A; Atsumi T; Dohi M; Hirata S; Kameda H; Nagasawa H; Seto Y; Koike T; Miyasaka N Mod Rheumatol; 2013 Mar; 23(2):284-96. PubMed ID: 22588312 [TBL] [Abstract][Full Text] [Related]
27. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918 [TBL] [Abstract][Full Text] [Related]
28. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Cinotti E; Labeille B; Perrot JL; Pallot-Prades B; Cambazard F Clin Exp Dermatol; 2014 Aug; 39(6):750-1. PubMed ID: 24984791 [No Abstract] [Full Text] [Related]
29. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Williams VL; Cohen PR Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984 [TBL] [Abstract][Full Text] [Related]
30. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. Dias OM; Pereira DA; Baldi BG; Costa AN; Athanazio RA; Kairalla RA; Carvalho CR J Bras Pneumol; 2014; 40(1):77-81. PubMed ID: 24626274 [TBL] [Abstract][Full Text] [Related]
36. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347 [TBL] [Abstract][Full Text] [Related]
37. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984 [TBL] [Abstract][Full Text] [Related]